FDA Grants Accelerated Approval to Zanvastro (Zilganersen): First-Ever Targeted Therapy Approved for Rare Neurological Disorder Alexander Disease

SILVER SPRING, Md. — The U.S. Food and Drug Administration (FDA) has officially approved Zanvastro (zilganersen), developed by Ionis Pharmaceuticals, making it the world’s first targeted therapeutic option for patients diagnosed with Alexander disease. ​Alexander disease is an extremely rare and progressive neurological condition belonging to the family of leukodystrophies. Caused by mutations in the GFAP (glial fibrillary acidic protein) gene, the condition leads to an abnormal buildup of proteins in astrocytes within the brain, causing a breakdown of the myelin sheath that protects nerve fibers. For decades, standard care was strictly palliative, leaving families with no treatment options to slow the course of the disease. ​Zanvastro is a GFAP-directed antisense oligonucleotide (ASO) administered via spinal injection. The therapy works at the genetic level by binding directly to the messenger RNA (mRNA) produced by the mutated GFAP gene, prompting its degradation before toxic protein aggregates can accumulate in brain tissue. ​In clinical trials, the treatment demonstrated a statistically significant reduction in GFAP protein concentrations in patients' cerebrospinal fluid, accompanying improvements and stabilization in motor function and neurological assessments compared to historical natural history cohorts. ​"The approval of Zanvastro represents a monumental shift from symptomatic management to precise genetic targeting for rare neurodegenerative conditions," said representatives during the regulatory announcement. The drug received Priority Review and Orphan Drug designations from the FDA to expedite its route to clinical availability. Medical centers across the United States are expected to begin administering the drug to eligible patients in the coming weeks.